Evidence map›Paper›PMID 38932280›Full record

ArticleViruses2024

The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice.

Anna Ivanina, Irina Leneva, Irina Falynskova, Ekaterina Glubokova, Nadezhda Kartashova, Nadezda Pankova, Sergei Korovkin, Oxana Svitich

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna IvaninaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.ORCID 0000-0002-7289-693X
Irina LenevaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.
Irina FalynskovaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.ORCID 0000-0001-9836-9620
Ekaterina GlubokovaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.ORCID 0000-0002-5925-9733
Nadezhda KartashovaMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.ORCID 0000-0003-2096-5080
Nadezda PankovaOOO Firn M, Biotech Company, 108804 Moscow, Russia.ORCID 0000-0001-7474-3665
Sergei KorovkinOOO Firn M, Biotech Company, 108804 Moscow, Russia.ORCID 0000-0002-6565-6794
Oxana SvitichMechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are widespread human pathogens that establish chronic latent infections leading to recurrent episodes. Current treatments are limited, necessitating the development of novel antiviral strategies. This study aimed to assess the antiviral efficacy of novel topical formulations containing interferon alpha-2b (IFN α-2b) against HSV-1 and HSV-2. The formulations, Oftalmoferon

Indexed as

Antiviral AgentsDisease Models, AnimalHerpes GenitalisHerpesvirus 1, HumanHerpesvirus 2, HumanKeratitis, HerpeticAdministration, TopicalAnimalsChlorocebus aethiopsFemaleHumansInterferon-alphaInterferon alpha-2MiceOphthalmic SolutionsRabbitsAntiviral AgentsInterferon-alphaInterferon alpha-2Ophthalmic Solutionsgenital herpes infectionherpetic stromal keratitisHSV-1HSV-2interferon alpha-2btopical formulations

Identifiers

PMID38932280
PMCPMC11209562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.